Global Intravitreal Injectable Market Growth 2025-2031

Global Intravitreal Injectable Market Growth 2025-2031

The global Intravitreal Injectable market size is predicted to grow from US$ 16290 million in 2025 to US$ 24950 million in 2031; it is expected to grow at a CAGR of 7.4% from 2025 to 2031.

Intravitreal Injectable are shot of medicine into the eye. It was first used to administer drugs to treat endophthalmitis and cytomegalovirus retinitis. Recently, it is used to treat age-related macular degeneration and many other retinal diseases as well.

Global Intravitreal Injectable key players include Regeneron Pharmaceuticals (Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, Kanghong Pharmaceutical, etc. Global top five manufacturers hold a share over 70%.

North Amercia is the largest market, with a share over 50%, followed by Europe and Asia-Pacific, both have a share over 40 percent.In terms of drug, Anti-VEGF is the largest segment, with a share over 85%. And in terms of disease, the largest application is Macular Edema, followed by Macular Degeneration, Retinal Vein Occlusion, etc.

LP Information, Inc. (LPI) ' newest research report, the “Intravitreal Injectable Industry Forecast” looks at past sales and reviews total world Intravitreal Injectable sales in 2024, providing a comprehensive analysis by region and market sector of projected Intravitreal Injectable sales for 2025 through 2031. With Intravitreal Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injectable industry.

This Insight Report provides a comprehensive analysis of the global Intravitreal Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravitreal Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injectable market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injectable and breaks down the forecast by Drug, by Disease, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injectable.

This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injectable market by product type, application, key manufacturers and key regions and countries.

Segmentation by Drug:
Anti-VEGF
Steroids
Others

Segmentation by Disease:
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Allergan
EyePoint Pharmaceuticals
Genentech
Kanghong Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Intravitreal Injectable market?

What factors are driving Intravitreal Injectable market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Intravitreal Injectable market opportunities vary by end market size?

How does Intravitreal Injectable break out by Drug, by Disease?

Please note: The report will take approximately 2 business days to prepare and deliver.